Core Insights - ZimVie Inc. has become a privately held company following its acquisition by ARCHIMED, an investment firm focused on healthcare industries [1][2] - The acquisition involved ARCHIMED purchasing all outstanding shares of ZimVie stock at a price of $19.00 per share, leading to ZimVie's common stock being delisted from NASDAQ [2] Company Overview: ZimVie - ZimVie is a global leader in the dental implant market, developing and delivering a comprehensive range of products for dental tooth replacement and restoration [4] - The company is headquartered in Palm Beach Gardens, Florida, and aims to enhance smiles and confidence through its innovative dental solutions, including implants and digital workflows [4] Company Overview: ARCHIMED - ARCHIMED is a leading investment firm with a focus on healthcare industries, managing €8 billion across various funds [5] - The firm combines operational, medical, scientific, and financial expertise to support healthcare businesses in areas such as MedTech, Biopharma, and Diagnostics [5] - ARCHIMED is committed to impact investing and aims to help partners innovate and expand their services [5]

Core Viewpoint - ZimVie Inc. has received approval from its stockholders for the acquisition by an affiliate of ARCHIMED, with the merger expected to close on October 20, 2025, pending all conditions being met [1][2]. Company Overview: ZimVie - ZimVie is a global leader in the dental implant market, focusing on developing, manufacturing, and delivering a wide range of products for dental tooth replacement and restoration [3]. - The company aims to enhance smiles, function, and confidence through its comprehensive solutions, which include dental implants, biomaterials, and digital workflow solutions [3]. - ZimVie operates from its headquarters in Palm Beach Gardens, Florida, and has additional facilities worldwide [3]. Company Overview: ARCHIMED - ARCHIMED is a prominent investment firm with a focus on healthcare industries, operating in Europe, North America, and Asia [4]. - The firm combines operational, medical, scientific, and financial expertise to act as both a strategic and financial partner for healthcare businesses [4]. - ARCHIMED manages €8 billion across various funds and emphasizes impact investing through its EURÊKA Foundation [4].

Core Points - ZimVie Inc. will report its financial results for Q2 2025 on July 30, 2025, after market close [1] - ZimVie has entered into a definitive agreement to be acquired by an affiliate of ARCHIMED for $19.00 per share in cash [2] - The acquisition is expected to close by the end of 2025, pending stockholder and regulatory approvals [3] Company Overview - ZimVie is a global leader in the dental implant market, focusing on developing and delivering products for dental tooth replacement and restoration [4] - The company aims to enhance smiles, function, and confidence through its comprehensive portfolio, which includes dental implants, biomaterials, and digital workflow solutions [4] Transaction Details - Upon completion of the acquisition, ZimVie will become a privately held company, and its shares will no longer be traded on NASDAQ [3] - Due to the pending acquisition, ZimVie will not hold a conference call for Q2 and has withdrawn its fiscal 2025 guidance [3]

Core Viewpoint - ZimVie Inc. has entered into a definitive agreement to be acquired by ARCHIMED, an investment firm focused on healthcare industries, for $19.00 per share, representing a 99% premium over its recent trading price, with an enterprise value of approximately $730 million [2][3]. Company Overview - ZimVie is a global leader in the dental implant market, developing and delivering a comprehensive portfolio of products aimed at supporting dental tooth replacement and restoration procedures [8]. - The company is headquartered in Palm Beach Gardens, Florida, and is committed to advancing clinical science and technology in the dental sector [8]. Acquisition Details - Under the merger agreement, ZimVie stockholders will receive $19.00 in cash for each share, with the transaction expected to close by year-end 2025, pending customary closing conditions [2][4]. - The Board of Directors of ZimVie has unanimously approved the transaction, which is not subject to a financing condition [4]. - Upon completion, ZimVie will become a privately held company, and its shares will no longer be listed on NASDAQ [5]. Strategic Implications - The acquisition is expected to provide ZimVie with the strategic and financial backing necessary to expand its innovative dental technology globally [3]. - ARCHIMED views ZimVie as having strong fundamentals and compelling growth potential, indicating a positive outlook for the company's future [3]. Go-Shop Period - ZimVie has a 40-day go-shop period during which it can solicit proposals from third parties, ending on August 29, 2025 [6]. - There is no assurance that this solicitation process will yield a superior proposal [6]. Advisory Roles - Centerview Partners is serving as the exclusive financial advisor to ZimVie, while UBS Investment Bank is the exclusive financial advisor to ARCHIMED [7].

Company Overview - ZimVie Inc. is a global leader in the dental market, focusing on life sciences and offering a comprehensive portfolio of products for dental tooth replacement and restoration procedures [2] - The company is headquartered in Palm Beach Gardens, Florida, and operates additional facilities worldwide [2] - ZimVie aims to enhance smiles, function, and confidence through its dental implants, biomaterials, and digital workflow solutions [2] Upcoming Events - ZimVie management will participate in the Stifel 2025 Jaws & Paws Conference, scheduled for May 28, 2025, at 3:00 p.m. Eastern Time [1] - A live webcast and archived recording of the event will be available on ZimVie's investor website [1]

Company Overview - ZimVie Inc. is a global leader in the dental market, focusing on life sciences and offering a comprehensive portfolio of products for dental tooth replacement and restoration procedures [2][3] - The company is headquartered in Palm Beach Gardens, Florida, and operates additional facilities worldwide [2] Financial Results Announcement - ZimVie will report its financial results for the first quarter of 2025 after market close on May 8, 2025 [1] - A conference call will be hosted by company management at 4:30 p.m. Eastern Time on the same day [1] Conference Call Details - Interested participants can register online to listen to the conference call, with a recommendation to register more than 15 minutes before the start [2] - A replay of the webcast will be available on the investor section of ZimVie's website [2]